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Although vigorous immune responses are required to pre-
serve a healthy state, a plethora of undesired immune reactions
can also occur, such as systemic autoimmunity, allograft rejec-
tion and nephritogenic processes. T cells are the dominant cell
type present in many of these unwanted reactions and are
responsible for tissue damage. For example, in insulin depen-
dent diabetes mellitus (IDDM) both CD4+ and CD8+ lympho-
cytes infiltrate the islets and trigger immunologically-mediated
beta cell destruction [1—7]. Studies in animal models and human
disease indicate that insulitis requires intact T cell dependent
immune function. Splenic T cells obtained from diabetic NOD
mice can transfer diabetes to younger non-diabetic NOD mice
[8]. Both CD4+ T cells are required to transfer the diabetic
state from diabetic hosts to young syngeneic animals [9, 10].
Treatment of experimental animals with anti-T cell antibodies
[11, 12], anti-CD4 monoclonal antibodies [7], anti-IL-2 receptor
monoclonal antibodies [13], neonatal thymectomy [14], total
lymphoid irradiation [15] or cyclosporine [16, 17] can all pre-
vent progressive beta cell loss. Many of the undesirable im-
mune reactions characteristic of IDDM can also be identified in
the tissues and inflammatory sites of other autoimmune dis-
eases during allograft rejection and in nephritogenic states.
Thus, it is not surprising that therapeutic strategies directed
toward eliminating or blocking T cell functions in experimental
diabetes also abort many undesired immune reactions in a
variety of nephritogenic processes.
T cell activation and tissue destruction
Our studies indicate that tissue destruction such as in insulitis
and allograft rejection is a CD4+, IL-2 receptor + T cell
dependent process that results in diffuse CD4+ and CD8+ cell
tissue infiltration. Rejection is mediated by a diverse assembly
of WBCs—including cytotoxic T cells, helper T cells, antibody
forming B-cells and macrophages [reviewed in 18]. The inflam-
matory process is similarly and totally dependent upon a small
population of T cells that hear recognition units, that is,
receptors, for unidentified autoantigens. Undesired inflamma-
tion, mediated by hoth CD4 and CD8+ T cells [6, 7, 9, 10], is
caused by the encounter of autoimmune T cell clones with the
autoantigens and results in T cell activation and proliferation.
This cascade of activation-associated events culminates in a
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remarkable amplification of immune activity. These events
serve to attract a large number and wide variety of activated
WBCs into the graft.
Let us trace this cascade of events. Helper cells rivet their
attention on antigens presented in association with surface
HLA class II molecules such as DR; helper T cells, bearing the
distinctive CD4 protein, are not activated by antigens presented
in association with class I molecules. By comparison, cytotoxic
T cells, bearing the CD8 protein, are activated primarily via
recognition of antigens associated with class I HLA molecules.
While antigen is necessary to activate T cells, full antigen-
stimulated T cell activation and proliferation requires additional
external signals delivered by accessory cells such as dendritic
cells or macrophages [19—21]. While antigen is the first required
external signal initiating T cell activation the second signal is
delivered by the accessory cells. It is possible that accessory
cell membrane-bound interleukin- 1 (IL- 1) is pivotal in T cell
activation [19—21]. Our as yet unpublished data indicates that
accessory cell derived interleukin-6 (IL-6) is even more impor-
tant than T cell activation. Following activation by antigen and
accessory cells, T cells are stimulated to secrete the T-cell
growth factor interleukin-2 (IL-2) and express, de novo, cell-
surface interleukin-2 receptors (IL-2R) [20—241. De novo
expression of IL-2R and release of IL-2 are of central impor-
tance in the events of T cell activation because the interaction
of IL-2 and IL-2R stimulates clonal proliferation of both anti-
gen-activated helper—and cytotoxic—T cells [23]. IL-2 also
stimulates antigen-activated T-cells to release several other
lymphokines that are critical to T-cell activation [25—28]. Anti-
gen-activated, IL-2 stimulated T-cells release B-cell activation
factors [27, 28], enabling antigen activated B-cells to elaborate
high affinity, high titer antibodies. IL-2 causes helper cells to
release factors that unleash the cytotoxic capacity of cytotoxic
T cells. IL-2 stimulates release of gamma interferon [25].
Gamma interferon, in turn, activates the cytodestructive activ-
ities of macrophages and stimulates tissues, such as islet cells,
that normally do not express HLA class II molecules to express
them [29, 30]. Moreover, IL-2 is an anabolic factor essential for
the viability of activated T cells [31]. Hence, IL-2 dependent
mechanisms result in activation of B cells, helper cells, cyto-
toxic cells and macrophages. Moreover, IL-2 dependent secre-
tion of gamma interferon causes the target tissue to sprout new
HLA molecules, and thus initiate a vicious cycle of cell-
mediated immune events.
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The impact of immunosuppressive agents can only be fully
appreciated by a thorough understanding of the events of T cell
activation. These events must now be examined in even greater
detail. As previously noted, T cell activation is initiated when
those few clones of T cells bearing cell surface receptors
specific for the stimulating antigens actively bind to these
antigens. Engagement of T cell receptors with antigen stimu-
lates formation of intracellular second messengers that trans-
duce signals from the cell membrane to the cell nucleus [22, 32,
33]. From this membrane event, cytoplasmic signal transduc-
tion activates genes that are required for T cell activation.
Investigations in many laboratories, indicate that cytoplasmic
second messengers formed in response to antigen stimulation
result from activation of membrane fatty acids leading to
hydrolysis of inositol triphosphates, activation of protein kinase
C and a precipitous rise in cytosolic calcium. These signals arise
as a consequence of receptor-induced hydrolysis of membrane
phospholipids yielding inositol triphosphate which releases
Ca2 from intracellular stores. A second source of intracellular
Ca2 results from a inositol triphosphate dependent opening of
calcium channels [33]. These second messengers activate IL-2R
genes; IL-2R encoding messenger RNA is transcribed; the
receptor protein is translated and inserted into the plasma
membrane. Recent investigations prove that high affinity
growth promoting IL-2Rs are heterodimers comprised of the
p55 Tac protein and a newly discovered p70 IL-2 binding
peptide. While antigen activation is necessary for T cell activa-
tion, it is not sufficient for T cell proliferation since antigen
activation alone does not lead directly to IL-2 release [20—22].
Formation of IL-2Rs may possibly be an antigen-driven, mac-
rophage independent process, but IL-2 release is strictly depen-
dent upon accessory cells.
Therefore, accessory cell activation is required for support of
full T cell activation. Direct cell to cell contact between antigen
activated T cells and macrophages, or stimulation of macro-
phages by soluble T cell products cause macrophage activation
and results in signal transduction probably via formation of
intracellular second messengers. These as yet unidentified
second messengers, in turn, activate the tumor necrosis factor
(TNF) and IL-i genes. Transcription of IL-i encoding mRNA
proceeds, and translation of large alpha and beta pro-IL- 1
molecules occurs [34, 35]. Precursor IL-l molecules are cleaved
intracellularly, and the considerably smaller mature forms of
IL-l are secreted. Potent, T cell stimulatory membrane-bound
forms of IL-l also exist. TNF is also translated as a propeptide
with a 76 amino acid appendage at the N-terminus of the human
peptide [36]. Both these monokines may be directly involved in
tissue destruction. IL-l and TNF are pleiotropic molecules with
overlapping function. Both are directly cytotoxic to several cell
types. IL-i has been demonstrated to directly cause tissue
destruction [37], while TNF, potentiates cytodestructive effects
[38]. IL-l and TNF also activate of the IL-6 gene in accessory
cells.
Following the dual stimulation of T cells by antigen and
accessory cells, a most critical step in T cell activation takes
place [20—22]. As previously noted, antigen activation stimu-
lates a pathway of events leading to de novo expression of
receptors for IL-2. We have noted that soluble IL-6 also
provides a second signal that elicits IL-2 gene activation in
antigen activated T-celis. Stimulation of the antigen activated,
IL-l receptor accessory bearing cells with membrane bound
IL-l results in signal transduction which serves to activate the
IL-2 gene. Messenger RNA for IL-2 is transcribed, translated,
processed and released. These activated T cells become capa-
ble of producing and responding to IL-2. With the appearance
of IL-2Rs and secretion of IL-2, the T-cell autocrine system is
now activated [22, 23].
Activation of IL-2 receptor bearing T cells by antigen acti-
vated IL-2 stimulates the formation of intracellular second
messengers which, in turn, activate other lymphokine genes,
including those for gamma interferon and IL-4 [25—28]. IL-2
thus serves a crucial role in eliciting T-cell-derived bioactive
proteins called lymphokines that activate T cells, B cells and
macrophages. Hence, the initial response of a small number of
antigen-specific T cell clones ultimately results in activation of
a diverse ensemble of WBCs through a variety of IL-2 depen-
dent events.
Activation of IL-2R bearing T cells by the T cell growth
factor IL-2 stimulates T cell proliferation. Thus, clonal expan-
sion of small numbers of T cells initially activated by cell
antigen is achieved. Propagation and expansion of these auto-
reactive T-cell clones enables establishment of the critical mass
of antigen activated T-cells required for tissue destruction.
Nature has provided a means to ensure that antigen-stimu-
lated T-cell lymphoproliferation can be limited. As time tran-
spires following antigen activation, transcription of lymphokine
and IL-2 receptor encoding messenger RNA slows, and the
remaining transcripts, inherently labile molecules, degenerate
[39]. The 3' flanking sequences of many cytokine mRNAs
including TNF, growth factors, growth factor receptor genes as
well as proto-oncogenes contain various forms of a consensus
octamer sequence UUAUUUAU that render these transcripts
inherently labile [39]. Thus, T cell proliferation is halted and T
cells no longer secrete or express receptors for IL-2.
The immunopharmacology of T cell activation
Three drugs have gained wide acceptance as useful in pre-
vention of renal allograft rejection and other cell-immune me-
diated processes; these include corticosteroids, cyclosporine,
and azathioprine. Each of these 3 drugs blocks T cell prolifer-
ation, albeit by quite different means [reviewed in 40].
While corticosteroids block T cell proliferation, it is ironic
that the primary target of corticosteroids may not actually be
the T cell. Corticosteroids prevent T cell proliferation in part
through their ability to block activation of accessory cells. For
example, corticosteroids block activation of the IL-i gene [41].
We have noted that low concentrations of corticosteroid-
treated resting macrophages do not produce IL-i encoding
messenger RNA even when cultured in the presence of power-
ful macrophage stimulants. Once accessory cell activation has
commenced, higher doses of corticosteroids can block IL-i
[42], TNF and IL-6 release via post-transcriptional mecha-
nisms. As activated accessory cells are a prerequisite for IL-2
release, corticosteroids indirectly block the release of IL-2.
Cyclosporine blocks the T-cell activation cascade at a more
distal step than corticosteroids. In the presence of cyclo-
sporine, select elements of T cell activation proceed. Cyclo-
sporine does not prevent activation of the Tac IL-2R gene.
Hence, IL-2Rs are expressed on the surface of antigen stimu-
lated T-cells despite the presence of cyclosporine. However,
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cyclosporine blocks the IL-2 gene activation and prevents IL-2
synthesis [431.
Azathioprine, the first immunosuppressive utilized in organ
transplantation, also blocks T cell activation but at a point more
distal to the T cell activation blocks imposed by corticosteroids
and cyclosporine. Azathioprine, an antimetabolite drug, is the
imidazole derivative of 6-mercaptopurine [401. Azathioprine is
catabolized in vitro to 6-mercaptopurine and other antimetabo-
lites. Thus, azathioprine does not prevent initial gene activa-
tion, but potently inhibits gene replication and T cell prolifera-
tion. While azathioprine, corticosteroids and cyclosporine are
effective they are certainly not ideal immunosuppressive
agents. An ideal immunosuppressive drug should not only be
effective, but should specifically block the activities of only the
small population of cells actually engaged in the events of the
undesired immune response. In this regard, the shortcomings of
current drug immunosuppressive therapies are obvious. Con-
ventional drug therapies exert side effects on non-lymphoid
tissues. These drugs also impair the function of all T cells, not
just the small proportion of T cells that mediate undesired
immune events.
Toward selective immunosuppression
New high technological approaches have great promise for
refining the focus of immunosuppressive protocols. Invariant,
constant domains of the T-cell antigen receptor complex can
now be directly targeted for therapy by use monoclonal anti-
bodies. Six non-covalently linked T-cell surface proteins com-
prise the T-cell antigen recognition complex [43]. These six
proteins are expressed on essentially every functionally active
T-cell. The alpha and beta chains are the actual T-cell receptor
(TCR) antigen binding proteins. Monoclonal antibodies defining
an invariant combinatorial sequence of these alpha and beta
chains have been developed. The more distal portions of the
alpha and beta chains are unique and complementary for each
antigen. The other four proteins are referred to as the CD3
proteins and play a key role in transducing signals from the
antigen binding alpha and beta chains to the interior of the T cell
[20, 32]. The therapeutically-useful OKT3 monoclonal antibody
binds to one of the CD3 proteins. Hence, OKT3 in essence
binds to a constant or non-varying component of the T-cell
antigen recognition (TCR!CD3) complex.
When allograft rejection occurs despite maintenance drug
therapy, OKT3 is remarkably effective in reversing cellular
rejection [441. OKT3 is a considerably more powerful immuno-
suppressive agent than monoclonal antibodies that bind to
T-cells specific surface proteins not belonging to the T-cell
antigen recognition complex. When OKT3 binds to the T-cell
antigen recognition complex, each of its six constituent proteins
is stripped from the cell surface or internalized [451. Capping of
the surface of TCRICD3 binding molecules prevents the T cell
proliferative response to antigens and blocks cytolytic function.
Evidence has also accrued that this molecule conveys the
activation signal transduced from the TCR alpha and beta
chains [20, 45]. The transduced signal flows from the TCR
through the CD3 proteins into the interior of the cell. Indeed,
the first and occasionally second dose of OKT3 results, almost
instantly, in fever, chills, myalgia and capillary leak type
syndrome. Hence, OKT3-treated T cells lose their antigen
receptor proteins and become literally blinded as to the pres-
ence of the allograft; thus, rejection abates. The advent of
pan-T cell monoclonal antibodies such as OKT3 represents an
important refinement in therapy as these agents bind only to T
cells. In rodent models anti-T cell monoclonal antibodies are
effective in preventing lupus nephritis. Toxicity to non-lym-
phoid tissues, as occurs with conventional drugs, is obviated.
Nonetheless, OKT3 does not represent an ideal therapeutic
solution insofar as all T cells are targeted by this agent, and a
troublesome symptom complex linked to T cell stimulation
occurs with the first injection of OKT3. An ideal immunosup-
pressive therapy should, of course, be effective in controlling
the unwanted autoimmune process. This perfect therapy should
also selectively target only those T cells that are committed to
participate in the tissue destruction.
The ideal immunosuppressive therapy can be realized by
breaking the lock and key arrangement that intimately engages
antigens with those T cells bearing receptors that stereospeci-
fically recognize the stimulating antigen. This approach would
leave an overwhelming majority of immune cells involved in
protective host defense mechanism untouched, thus avoiding
the undesirable consequences of generalized immunosuppres-
sion. This solution would be obtained by developing antibodies
that react with the antigen combining site of T-cell antigen
receptors for antigens. This strategy has been confounded at
least temporarily by the genetic diversity of the T cell receptor
for antigen. As predicted from knowledge of the extensive gene
shuffling rearrangements, at least 1,000,000 forms of the T cell
receptor exist. Too many reagents would be required for
clone-specific immunosuppressive therapy to be a practical
therapeutic solution unless autoreactive T-cell clones are oligo-
clonal and similar in each patient.
Antigen binding domains of individual T-cell receptors can-
not be easily targeted and so we developed the simpler ap-
proach of targeting the IL-2R. In essence, only recently acti-
vated T-cells bear this structure, which is one of the plasma
membrane receptors that is absent from the surface of resting
cells as well as from non-lymphoid tissues [46].
The central importance of the interaction of IL-2 with newly
formed IL-2Rs has been emphasized; however, only vigorously
proliferating T cells bear high affinity IL-2Rs [23, 46]. Resting T
cells and memory T cells, such as those stimulated weeks
months or years ago by vaccines or previous encounters with
microbes, lack IL-2Rs.
This receptor is only transiently expressed during the brief
proliferative burst of lymphocytes triggered in response to
antigen. As the receptor is not expressed upon either resting or
long-term memory cells, we first wondered whether administra-
tion of anti-IL-2R monoclonal antibodies in the early post-
transplant period or in autoimmune hosts in animals undergoing
cell-mediated immune reactions would provide a utilitarian
approach to achieving selective immunosuppression. In theory,
a single antibody directed against a receptor protein expressed
in the common pathway of T cell activation can be used in every
situation to achieve selective immunosuppression. For this
purpose, we have developed a series of anti-IL-2R monoclonal
antibodies. It is remarkable that many mouse cardiac trans-
plants, engrafted across major transplantation barriers, are
permanently engrafted following a single 10 day course of rat
anti-mouse anti-IL-2R monoclonal antibody (Table 1) [47].
Delayed use of the antibody can totally reverse ongoing cardiac
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Table 1. Anti-IL-2 monoclonal antibody, M7/20, prolongs survival
of murine heart allografts
Recipients Donor Treatment Allograft survival days
B10.AKM C57B1/10 None 8,8,8,8,16,29
B10.AKM CB7B1/10 M7/20 20,31,>90,>90,>90,>90
B. I0.AKM C57B1/I0 RA3-2C2 6,9,9,10,>90
BIO.AKK C57B1/l0 AMTI3C 12,15,16, 17,20,23,24,>60>60
C57B 1/10 B10.BR None 9,10,10,10,14,16,20,20
C57B1/10 B 10.BR M7/20 0,27,34,38,>60>60
CS7BI/10 B10.BR M7/20, day 3 11,15,17, 18,47,>60,>60,>60
C57B1/l0 B10.BR M7/20, day 6 7,17,19,27d,21b58,>60,>60
5 tg i.p. daily for 10 days beginning day 6b Died of anesthetic complication with functioning allograft
5 mg i.p. daily for 10 days
Table 2. Anti-IL-2 monoclonal antibody, ART 18 prolongs survival
of heart allografts
Donor Recipient ART 18 dose
Mean graft
survival
days
(LEW XBN)F1 LEW None 8 I
(LEW XBN)F1 LEW 25 sg/kg/day x l0 13 I
(LEW XBN)F1 LEW 100 sgIkg/day x l0 14 3
(LEW XBN)FI LEW 300 pg/kg/day x l0 21 I
(LEW XBN)F1 LEW 300 pg/kg/day x ioa +Cs 56 13
(LEW XBN)F1 LEW 300 pg/kg/day X 5 14 2
(LEW XBN)F1 LEW 300 pg/kg/day X 18 4
(LEW XBN)F1 LEW 300 g/kgIday x i0 +Cs 58 II
LEW WF None 8±2
LEW WF 300 sg/kg/day x ioa 16 1
a i.v. daily for 20 days beginning on day 0
b i.v. daily for 5 days beginning on day 5
graft rejection [48]. Dramatic effects have also been noted with
mouse-anti-rat antibodies in a rat heart transplant model (Table
2) [49, 50]. Despite cessation of therapy, graft rejection does not
occur. Passive transfer experiments indicate that while donor-
specific alloreactive helper cells are destroyed [50], donor
specific suppressor T cells [49] are spared the effects of anti-
IL-2R directed therapy. These data clearly demonstrate the
great importance of activated, IL-2R bearing lymphocytes in
the events of graft rejection. In several models, we have now
learned that the combined effects of anti-IL-2R antibody and
low dose cyclosporine are synergestic.
Anti-T cell, anti-CD4 and anti-IL-2R monoclonal antibodies
block autoimmunity
In certain murine models of lupus-like autoimmunity anti-T
cell [51, 521 or anti-L3T4 monoclonal antibody, which binds to
the CD4 protein can prevent [53] or ameliorate [54, 55] the
disease. Anti-L3T4 binds to two-thirds of all T cells and is a
very potent immunosuppressant in man. Apparently anti-
L3T4's defining some but not all epitopes are immunosuppres-
sive in rodent models of immunity. Thus far, potent, anti-
human CD4 monoclonal antibodies have not been identified but
their development for use in clinical practice is eagerly awaited.
Anti-L3T4 targets a broad population of helper T cells; it would
be desirable to target an even smaller subset of antigen acti-
vated cells. Because no means of precisely identifying the
undesirable clones are presently available, we have attempted
Table 3. Anti-LL-2R antibody prevents tissue destruction in
autoimmune murine diabetes and lupus nephritis
NOD mice Histologya No. with insulitis
Anti-IL-2R 0.7 0.4 3/7
Control 2.1 0.4 6/6
NZB x NZW Fl hybrid
Proteinuria
(%) Histologya
IgG
% gp7O
Anti-IL-2R 38 11b 37 b
Control 75 2.5 85 50
a (0-4)
b < 0.05
to target activated lymphocytes selectively for treatment. Our
approach in autoimmunity is again based on the knowledge that
activated T cells express a variety of receptors that are absent
from resting cells. One of these receptors, the IL-2R is not
found or has very little distribution on nonlymphoid tissues [20,
46]. Resting populations of human mononuclear cells bear less
than 2% IL-2R as detected by anti-Tac antibody, which targets
to an IL-2 binding protein that participates in the formation of
high and low affinity IL-2R [56, 57]. By comparison, every
recently activated, proliferating T cell and some recently acti-
vated B cells bear high affinity IL-2R [58—61]. Hence, anti-IL-
2R monoclonal antibodies should primarily target a discrete
population of recently activated cells as well as a small popu-
lation (2%) of "resting" mononuclear leukocytes.
We have tested the hypothesis that IL-2R activated cells
initiate a programmed set of events that culminate in undesired
immune reactions using two models of autoimmunity. Treat-
ment with the anti-IL-2R M7120 antibody, which recognizes the
55kDa subunit of the high affinity heterodimeric IL-2R [62]
reduced the autoimmune insulitis characteristic of the nonobese
diabetic (NOD) mouse and protected NZB x NZW Fl female
hybrid mice from the development of renal injury in this model
of lupus [13].
Treatment with M7/20 suppressed insulitis in NOD mice
(Table 3). Four of the seven M7/20-treated mice did not develop
any evidence of insulitis whereas all six of the control animals
treated with a control antibody exhibited an inflammatory cell
infiltrate within their islets. Treatment with the control mono-
clonal antibody did not accelerate insulitis because previous
studies report a 89.7% incidence in femal NOD at nine weeks of
age. The degree of insulitis was 0.7 0.4 (on a 0 to 4 scoring
scale) in the M7/20 treated group as compared with 2.1 0.5 in
mice given the control antibody.
As previously noted, the response of lupus-prone strains of
mice to anti-T cell or anti-CD4 mAb therapy provides evidence
that certain forms of autoimmunity are dependent upon T cells,
especially CD4+ T cells as has been demonstrated in NZB x
NZW Fl and BXSB mice using an anti-L3T4 monoclonal
antibody [53, 54]. Treatment with highly purified anti-IL-2R
monoclonal antibody has the same effect but represents a more
refined approach insofar as IL-2R are expressed only by a small
subset of activated cells and a minor population of lymphokine-
activated killer and natural killer cells (Table 3); whereas
anti-CD4 binds to most mouse T cells, anti-IL-2R antibody
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binds to only 2 to 3% of mononuclear leucocytes in disease-free
animals.
These studies show that the anti-IL-2R monoclonal antibody
is effective in preventing autoirnmunity and indicate an impor-
tant role for IL-2R positive cells in the causation of autoimmune
induced tissue damage. Because the monomeric 55-kDa IL-2
binding protein is more abundantly expressed upon activated T
cells than the heterodimeric high-affinity receptor, treatment
with M7/20 is not necessarily the same as targeting the IL-2
high-affinity receptor [46]. Future studies will explore the
therapeutic use of this monoclonal antibody to treat, rather than
prevent, these autoimmune diseases.
Another "discrete" therapeutic approach, anti-Ia monoclo-
nal antibody treatment has proved effective in some murine
forms of autoimmunity, including the lupus NZB x NZW
hybrid, experimental allergic encephalitis, and the diabetic BB
rat [63—65]. Quantitative variation in La expression plays a
central role in immune regulation. Increased class II MHC (Ia)
expression on antigen-presenting cells is triggered after birth
and Ia expression is increased during the early autoimmune
events before tissue injury in several lupus strains and the
diabetic BB rat. Although it is possible that enhanced Ia
expression in autoimmune strains results from a preprogram
genetic event in Ia gene independent of external influences, the
release of lymphokine such as interferon-gamma or IL-4 from
activated T cells can stimulate expression of Ia. Anti-Ia treat-
ment in these autoimmune situations also diminishes disease
expression.
The present studies showing suppression of spontaneous
autoimmunity with a monoclonal antibody which binds to the
IL-2R and blocks the binding of IL-2, underscore the impor-
tance of a small population of activated T helper cells in the
series of immunologic reactions that lead to autoimmune tissue
injury. It is likely that IL-2R+-activated T cells elaborate
lymphokines, such as, interferon-gamma and/or IL-4, thereby
stimulating de novo expression of class II molecules with the
autoimmune lesion. De novo expression of lymphokine-induced
Ia molecules may create a vicious cycle leading to heightened
immune injury. Clearly, narrowly targeted approaches, for
example, anti-L3T4, anti-IL-2R and anti-Ia monoclonal anti-
bodies, yield valuable insights into basic mechanisms of autoim-
munity as well as provide potential therapeutic avenues for
regulation of other undesired immune reactions.
Anti-IL-2R monoclonal antibody treatment of subhuman and
human primate recipients of kidney allografts
The observation that anti-IL-2R monoclonal antibodies are
effective immunosuppressive agents in murine and rat trans-
plantation models provide an incentive for pre-clinical trials in
primates. Two IgG2a mouse anti-human IL-2R antibodies,
l-HT4-4H3 and anti-Tac, were found to react with ConA
activated, but not resting, M, fascicularis monkey lymphocytes
[66].
These antibodies were tested in a M. fascicularis renal
transplantation model [661. l-HTH4-4H3 treatment had no
effect on graft survival despite demonstrable circulating serum
mouse antibody. In contrast, anti-Tac treatment resulted in a
significant increase of both graft and recipient survival. As sole
therapy, anti-Tac prolonged graft survival to 14 days (P <0.01),
as compared to untreated controls, which reject by day 7 [66].
In nephrectomized recipients, anti-Tac therapy increased the
survival from 12 days to 15 to 22 days (P < 0.05). Although
addition of low-dose cyclosporine therapy resulted in a modest
prolongation of graft survival beyond that achieved with anti-
Tac alone, all grafts were eventually rejected.
Given the relative success of anti-IL-2R monoclonal antibod-
ies in rodent transplantation models, the ability of anti-Tac to
prolong the renal graft in M. fascicularis is not surprising. Thus,
the major question arises why is the anti-Tac effect so transient?
Nearly all monkeys treated with anti-Tac develop anti-mouse
antibodies. Interestingly, the time of the development of anti-
mouse antibodies are first detected just prior to rejection,
although this observation does not prove that the development
of anti-mouse antibodies leads to the eventual failure of anti-
Tac therapy. The reason why l-HT4-4H3 and anti-Tac produce
strikingly different effects is uncertain. Insofar as mouse anti-
primate antibodies fix human complement poorly, therapeutic
results equivalent to those obtained in the mouse and rat models
may await a more certain vehicle for effecting cytocidal hits on
IL-2R+ cells. Indeed, examination of the immunosuppressive
effects of anti-mouse IL-2R monoclonal antibodies reveal that
the most effective antibodies block IL-2 binding and fix com-
plement [67].
In Boston, Massachusetts, USA and Nantes, France, human
recipients of cadaver donor renal allografts are receiving two
different anti-IL-2R monoclonal antibodies as adjunctive ther-
apy. Antibody treatment is well tolerated, rejection is rare.
Virtually all recipients treated to date enjoy a functioning
allograft.
Monoclonal antibody may not provide the best vehicle for
targeting IL-2R+ cells, especially in clinical circumstances.
Murine antibodies fix human complement poorly; the affinity of
anti-IL-2R antibodies to the IL-2R is less than that of IL-2. We
have now completed the genetic construction, expression, and
demonstrations of selective cytotoxicity of a unique chimeric
protein, IL-2 toxin, whose sequence is the product of a gene
fusion between the cDNA encoding IL-2 and a portion of the
structural gene for diphtheria toxin in which the toxin receptor
binding domain has been replaced with IL-2 sequences [68].
The 68 kD chimeric toxin possesses antigenic determinants
associated with both IL-2 and diphtheria toxin proteins. IL-2
toxin dramatically inhibits protein synthesis in several IL-2R +
m HTLV-I infected human leukemic cell lines and the murine
IL-2 indicator line CTLL-2 [691. The mechanism by which
inhibition of protein synthesis involves the classic toxin-medi-
ated ADP—ribosylation of elongation factor 2 [68, 69]. IL-2
toxin-mediated inhibition of protein synthesis in HTLV-I in-
fected human T cells is IL-2R specific and can be selectively
blocked by either excess free IL-2 or anti-IL-2R monoclonal
antibody. Human T cell lines which are IL-2R negative are
resistant to the chimeric toxin. These in vitro studies suggest
that IL-2 toxin selectively binds to and intoxicates IL-2R+ T
lymphocytes, thus making this chimeric toxin an attractive
agent for IL-2 receptor-specific immunotherapy.
Chimeric IL-2 toxin prevents undesired immune reactions
Indeed, IL-2 toxin is a potent, selective immunotherapeutic
capable of preventing unwanted immune reactions [70]. IL-2
toxin suppresses DTH more potently than treatment with
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Table 4. IL-2 toxin destroys activated IL-2R + cells
IL-2R+ %
Lymph node CD4+ CD8+
Non-immunized 3 2
Immunized 14 18
Immunized IL-2-toxin 5 3
Analysis of 0.5 x io cells/sample
Table 5. IL-2 toxin prevents islet cell rejection in mice
Treatment Graft survival days
LL-2 toxina 17,25,30,34,34,35,100
CRM 45 13,15,17,19,31,
Noneb 6,7,7,11,13,14,22,27
IL-2 toxin vs. CRM 45 (the diphtheria toxin lacking the receptor
binding domain, P < 0.25.
IL-2 toxin vs. None, P < 0.001.
B6AFI recipients and DBA/2 donors.
Table 6. IL-2 toxin prolongs cardiac allograft survival
Treatment Graft survival days
LL-2 toxin 1.0 mg
LL-2 toxin 0.5 tng
CRM45 0.66mg
None
27,>50,>50,>50,>50a
12, 16, 19,41,>50
11,12,12,13,19
10,14,15,18,20
i.p. qd for 10 days P < 0.01
mice = B10.BR into C57B1/l0
CRM45 (diphtheria toxin lacking the receptor binding domain)
anti-IL-2R monoclonal antibody. Phenotypic analysis of drain-
ing lymph nodes from mice with induced DTH that IL-2R+
CD4 and CD8 cells are selectively eliminated during the course
of IL-2 toxin administration (Table 4). Insofar as immunization
with diphtheria toxoid is an important public health measure, it
is important to note that toxoid-treated immune mice with high
titers of neutralizing diphtheria anti-toxin antibodies are equally
as susceptible to the immunosuppresive action of the IL-2 toxin
as non-toxoid immune mice.
IL-2 toxin is a powerful anti-rejection therapeutic. We have
reported that treatment of IL-2 toxin alone prevents the rejec-
tions of a pancreatic islet preparation transplanted across major
and minor histocompatability barriers [71] (Table 5). Histo-
pathologic examination illustrates that IL-2 toxin reduces the
mononuclear cellular inflammation in the subcapsular site that
where islets have been transplanted. IL-2 toxin therapy in
heterotopic cardiac transplant causes an even more dramatic
prolonged engraftment (Table 6). In fact, these data suggest that
IL-2 toxin can induce tolerance. These studies underscore the
importance of IL-2R bearing cells in the induction of undesired
immune events. Thus, a therapeutic strategy with the lethal
precision of the IL-2 toxin offers enormous promise for treating
autoimmunity, allograft rejection and nephritogenic process.
Summary
Our results provide important evidence that IL-2 receptor
bearing cells are required for undesired immune reactions
involved in autoimmunity, allograft rejection and nephritogenic
processes. Administration of anti-IL-2 receptor monoclonal
antibodies prolonged vascularized heart allograft survival
across major histocompatibility barrier in mice and rats and
renal monkey grafts. Indeed, several grafts survived indefi-
nitely, although the antibody was administered only for the first
10 days post-transplantation. Rejection of the remaining grafts
may well reflect inadequate dosage of antibody; dose-response
studies have not been performed to date. In addition to pre-
venting rejection, delayed treatment with anti-IL-2R monoclo-
nal antibody was shown to reverse ongoing rejection in other
recipients of heart allografts. Such long-term engraftment fol-
lowing cessation of therapy makes it unlikely that anti-IL-2R
treatment prolongs graft survival by pharmacologic blockade of
the IL-2R. Furthermore, exogenous IL-2 does not diminish the
beneficial effects of anti-IL-2R antibody therapy in rodents.
Whether or not such prolonged graft survival represents dele-
tion of the responding T cell clones is a subject of current
investigation. Results in a delayed-type hypersensitivity model
indicate that complement fixation, is required to achieve opti-
mal immunosuppression. Moreover, only anti-receptor antibod-
ies that block IL-2 binding mediate optimal immunosuppres-
sion. Passive transfer experiments clearly prove that immediate
post-transplant courses of anti-IL-2R monoclonal antibody
spares suppressor T cells. In rodent models, delayed type
hypersensitivity and lupus and diabetic autoimmunity are pre-
vented by anti-IL-2R treatment.
Finally, the availability of monoclonal antibodies directed
against the human IL-2R provides an opportunity to extend this
principle to clinical transplantation. The presence of IL-2R on
all recently activated T-cells and their absence from the surface
of almost all resting or memory T cells makes it possible to
target only the relevant responding clones following an allo-
graft, raising the hope of highly selective immunosuppression.
In this regard, anti-Tac, which defines the human IL-2 receptor,
is effective in prolonging renal allograft survival in monkeys.
The unexpected necessity for high doses of antibody in the
monkey model may underscore the importance of complement
fixation as this antibody does not fix human complement.
IL-2 toxins may prove an especially powerful means to target
IL-2R+ cells. While anti-IL-2R antibodies are not endocytosed,
IL-2 is endocytosed. Hence, antibodies reacting with the IL-2R
seem unsuited to deliver toxins into the cytosol where toxins
mediate cytodestructive effects. IL-2, however, is subject to
receptor mediated endocytosis. IL-2 binds to the IL-2 binds to
the IL-2R with far greater affinity than anti-IL-2R monoclonal
antibodies. Insofar as high affinity, but not low affinity, IL-2R
endocytose IL-2, IL-2 toxins are potentially a more selective
therapeutic probe than the antibodies because high affinity
IL-2R present on a smaller population of lymphocytes than
those bearing low-affinity receptor sites. IL-2 toxins can be
developed by utilizing cross linked conjugates of IL-2 and
toxin, but the point of linkage cannot be absolutely guaranteed.
Hence a single isomer may not be produced. A mixture of
isomers may well contain both high affinity toxins and unde-
sired products.
In order to assure a uniform product, we have developed a
recombinant protein consisting of IL-2 and the desired portions
of diphtheria toxin. This toxin exerts devastating effects upon
IL-2R positive T blasts and leukemic lines in vitro and is a
potent, precise immunosuppressant in vivo cell mediated im-
munity and allograft rejection. It seems likely that it will soon
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be possible to effectively target, in a most selective manner,
alloactivated T cells via the IL-2 receptor. Monoclonal antibod-
ies, antibody toxin conjugates, or exotic IL-2 toxins afford
several potential means to specifically target the actual cells
activated by the donor graft. While the potency of such agents,
in clinical circumstances, is unproven, therapeutic targeting of
IL-2R+ activated lymphocytes does afford the most precise and
selective means of immunotherapy currently available for clin-
ical testing.
Reprint requests to Terry B. Strom, M.D., Renal Division, Beth
Israel Hospital, Boston, Massachusetts 02215, USA.
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